In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Nuclear Pharmacy Services

Latest From Nuclear Pharmacy Services

Healthy Convergence

Some health care firms have managed to work around the industry's well-documented growth constraints by pursuing a strategy of convergence--finding new combinations of formerly distinct market segments for pharmaceuticals, devices, and diagnostics. The authors, at Bain & Company, outline the considerations that drive the evaluation of and set the stage for convergence opportunities. Companies can use them to capitalize on an array of opportunities throughout the commercialization continuum and develop a response to potential threats from the outside.

BioPharmaceutical Medical Device

Deal Statistics Quarterly, Q2 2002

In Vivo presents another installment of our quarterly review of dealmaking--in this case April through June 2002. Our data come from Windhover's Strategic Transactions Database. We include medical device financings by deal type; diagnostic financings by industry segment; pharma and biotech alliances by therapeutic category and industry segment; pharma and biotech financings by market segment, and pharma and biotech M&A.

BioPharmaceutical Medical Device

Launching Zevalin

The market success of Zevalin, Idec Pharmaceutical's second product will largely depend on how well the company has built the requisite commercial infrastructure prior to launch. Idec benefited from having watched how Genentech handled the launch of Idec's first drug, Rituxan. But Zevalin raises unique issues including the need to establish a logistical framework for this first-of-its-kind regimen, in which radiation oncologists play a significant role in the therapy. A disappointment would heighten the uncertainty around the launch of other kinds of innovative products--Idec's certainly, and also those of other companies. The industry will be watching this as a barometer of potential for whether other highly complex therapies whose delivery entails the use of several types of specialists can succeed.

BioPharmaceutical Medical Device

Imaging in its Heyday: Clinical Applications (Part II)

As scientific innovation in molecular imaging explodes, experts believe the big payoff will be in clinical, rather than research, applications. But absent validating clinical data, businesses remain hesitant to jump into the field.

Medical Device Business Strategies
See All

Company Information

  • Industry
  • Services
  • Pharmaceuticals
    • Radiopharmaceuticals, Contrast Agents